Allogeneic Cell Therapy for EBV+ PTLD: EHA 2026 Insights

Epstein-Barr virus (EBV) infection is a common trigger for post-transplant lymphoproliferative disease (PTLD), a heterogeneous group of lymphoid proliferations that can occur after solid organ transplantation (SOT) or haematopoietic stem cell transplantation (HSCT).^1,3,6 EBV+ PTLD represents a serious complication, with incidence varying based on transplant type, immunosuppression regimen, and recipient EBV serostatus.^2,3 Untreated, it can progress rapidly, leading to organ dysfunction and death.^3,6 Current management strategies include reduction of immunosuppression (RIS), rituximab, and chemotherapy.⁴ But a substantial proportion of patients are refractory to these standard treatments, necessitating alternative therapeutic approaches.^2,3,5,6 The EHA 2026 presentation on allogeneic cell therapy for EBV+ PTLD focused on the evolving role of adoptive cellular immunotherapies in this clinical setting.⁶ The incidence of PTLD is higher in pediatric transplant recipients and in those receiving T-cell depleting agents. The risk is also elevated in patients who are EBV seronegative at the time of transplant and subsequently acquire primary EBV infection.³ Early diagnosis, often through monitoring of EBV viral load, directs timely intervention and improved outcomes. A significant unmet need persists for patients with refractory or relapsed EBV+ PTLD, particularly those with aggressive forms of the disease or those unable to tolerate further chemotherapy.^2,3,5,6

Allogeneic T-cells deliver high response rates without comparative trials

Allogeneic EBV-specific T-cell (EBV-CTL) therapies generate objective responses in patients with refractory EBV+ PTLD, though the data rely entirely on single-arm trials.^2,4-6 These trials typically enrolled patients with biopsy-proven EBV+ PTLD, often those who had failed initial therapies such as rituximab or multi-agent chemotherapy.^2,5,6 EBV-CTLs were generated from healthy EBV-seropositive donors, frequently the original transplant donor, or from third-party donors.^1,5,7 The manufacturing process involves stimulating donor peripheral blood mononuclear cells with EBV antigens to expand EBV-specific T-cells, which are then infused into the patient.^4,6,8 This ex vivo expansion aims to generate a specific T-cell product capable of recognizing and eliminating EBV-infected B cells and PTLD lesions.⁶ The mechanism of action relies on the cytotoxic activity of these T-cells against cells expressing latent EBV antigens, thereby restoring immune surveillance against the virus.⁶

Primary endpoints in these studies generally included objective response rate (ORR), complete response (CR) rate, duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety, particularly the incidence of graft-versus-host disease (GvHD).⁹ Pooled data from several studies indicated that allogeneic EBV-CTL therapy achieved an ORR ranging from 60% to 80% in patients with refractory EBV+ PTLD.^1,5,10 Complete responses were observed in approximately 40% to 60% of treated patients.^1,5,11 The median duration of response was frequently reported as durable, extending beyond 12 months in many responders.^5,12 One meta-analysis presented at the meeting showed a 2-year OS rate of 55% (95% CI, 48% to 62%) in patients receiving EBV-CTLs, a figure that compares favorably to historical controls with significantly lower survival rates following failure of conventional therapies.¹³ The safety profile was generally favorable, with GvHD occurring in a minority of patients, typically less than 10%, and often manageable.^5,14 The risk of GvHD was particularly low when using partially HLA-matched or third-party donor cells, or when cells were selected for specific EBV antigens.¹⁵ Cytokine release syndrome (CRS) was also observed but was generally mild to moderate and resolved with supportive care.¹⁶ Efficacy appeared consistent across both SOT and HSCT recipients, though the specific challenges of immunosuppression management differed between these populations.^5,6,17

These findings come from studies with inherent limitations that temper their immediate applicability. The relatively small sample sizes of individual trials and the heterogeneity in patient populations, prior treatments, and EBV-CTL manufacturing protocols mean that generalizability across all clinical scenarios requires caution.¹⁸ Most studies were single-arm, Phase 1 and 2 trials, lacking direct head-to-head comparisons with other therapeutic modalities.¹⁹ This design makes it difficult to definitively assess the comparative efficacy against existing treatments or to establish optimal treatment sequencing. The trials do not establish the optimal timing for EBV-CTL administration, the ideal cell dose, or the exact need for concomitant immunosuppression adjustment. Without randomized controlled data, clinicians cannot know whether early intervention with cellular therapy would outperform sequential chemotherapy regimens. The long-term immunological effects and potential for late toxicities also require continued monitoring.

For clinicians managing refractory EBV+ PTLD, these data suggest allogeneic EBV-CTL therapy offers a viable option where conventional treatments have failed.^2,6 The observed response rates and survival benefit in a difficult-to-treat population indicate a distinct clinical utility.^1,2,6 The development of off-the-shelf universal EBV-CTL products from third-party donors is an area of active investigation aimed at overcoming the logistical challenges of patient-specific cell generation.^4,5,21 This approach seeks to provide readily available treatment options, reducing the time from diagnosis to therapy.⁵ Clinicians should consider referring patients with rituximab-refractory disease to centers with access to these cellular products rather than cycling through increasingly toxic salvage chemotherapy.^2,3,5 Future research directions include optimizing EBV-CTL manufacturing, exploring combination therapies to enhance efficacy, and identifying biomarkers to predict both response and toxicity.²⁰ Until comparative trials read out, patient selection relies on balancing the immediate risk of uncontrolled lymphoproliferation against the logistical hurdles of accessing allogeneic cell products.